Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Adult Subjects with Generalized Pustular Psoriasis

Next Previous
Trial Profile

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Adult Subjects with Generalized Pustular Psoriasis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 Mar 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Imsidolimab (Primary) ; Imsidolimab (Primary)
  • Indications Generalised pustular psoriasis
  • Focus Registrational; Therapeutic Use
  • Acronyms GEMINI1
  • Sponsors AnaptysBio

Most Recent Events

  • 25 Feb 2026 According to Vanda Pharmaceuticals media release, the U.S. Food and Drug Administration (FDA) has accepted the filing of its Biologics License Application (BLA) for imsidolimab for the treatment of Generalized Pustular Psoriasis (GPP), with a target action date of December 12, 2026.
  • 15 Dec 2025 According to Vanda Pharmaceuticals media release, the company has requested priority review for the BLA, citing GPP as a rare orphan disease. The priority review would establish a 6-month review cycle, with a potential FDA approval of imsidolimab for the treatment of GPP as early as mid-2026.
  • 15 Dec 2025 According to an Vanda Pharmaceuticals media release, the company has submitted the BLA for Imsidolimab to the USFDA to treat generalized pustular psoriasis (GPP). The BLA is supported by positive results from the global Phase 3 GEMINI-1 and GEMINI-2 studies.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top